The healthcare overweighting was driven mainly by medical device-makers, with Globus Medical and Baxter added in the past year. Biotechs (Regeneron and Amgen) also played a key role here.

Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most peers, over a market cycle on a risk-adjusted basis. This small ...